Exploring the causal relationship between GLP-1R agonists and diseases related to the thyroid and parathyroid: a mendelian randomization study.

IF 1.6 Q4 ENDOCRINOLOGY & METABOLISM
Journal of Diabetes and Metabolic Disorders Pub Date : 2025-02-05 eCollection Date: 2025-06-01 DOI:10.1007/s40200-025-01567-y
Caihong Li, Keyu Shen, Lingfeng Pan
{"title":"Exploring the causal relationship between GLP-1R agonists and diseases related to the thyroid and parathyroid: a mendelian randomization study.","authors":"Caihong Li, Keyu Shen, Lingfeng Pan","doi":"10.1007/s40200-025-01567-y","DOIUrl":null,"url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor (GLP-1R) agonists are well-known for their benefits in managing obesity and diabetes. However, some studies indicate that they may elevate the risk of thyroid cancer. This study employed summary data-based Mendelian randomization (SMR) analysis, incorporating genetic data from GTEx V.8 and the UK Biobank, to assess how increased GLP-1R gene expression in thyroid and parathyroid tissues affects their functions. We found that increased expression of GLP-1R is a risk factor for hyperparathyroidism, but no causal relationship was found with thyroid dysfunction. Furthermore, we advise routine assessments of parathyroid function and hormone levels for patients on GLP-1R agonists.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01567-y.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"64"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799478/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Metabolic Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40200-025-01567-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) agonists are well-known for their benefits in managing obesity and diabetes. However, some studies indicate that they may elevate the risk of thyroid cancer. This study employed summary data-based Mendelian randomization (SMR) analysis, incorporating genetic data from GTEx V.8 and the UK Biobank, to assess how increased GLP-1R gene expression in thyroid and parathyroid tissues affects their functions. We found that increased expression of GLP-1R is a risk factor for hyperparathyroidism, but no causal relationship was found with thyroid dysfunction. Furthermore, we advise routine assessments of parathyroid function and hormone levels for patients on GLP-1R agonists.

Supplementary information: The online version contains supplementary material available at 10.1007/s40200-025-01567-y.

探索GLP-1R激动剂与甲状腺和甲状旁腺相关疾病之间的因果关系:一项孟德尔随机研究
胰高血糖素样肽-1受体(GLP-1R)激动剂因其在控制肥胖和糖尿病方面的益处而闻名。然而,一些研究表明,它们可能会增加患甲状腺癌的风险。本研究采用基于汇总数据的孟德尔随机化(SMR)分析,结合GTEx V.8和UK Biobank的遗传数据,评估GLP-1R基因在甲状腺和甲状旁腺组织中的表达增加如何影响其功能。我们发现GLP-1R的表达增加是甲状旁腺功能亢进的危险因素,但与甲状腺功能障碍没有因果关系。此外,我们建议对GLP-1R激动剂患者进行甲状旁腺功能和激素水平的常规评估。补充资料:在线版本提供补充资料,网址为10.1007/s40200-025-01567-y。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes and Metabolic Disorders
Journal of Diabetes and Metabolic Disorders Medicine-Internal Medicine
CiteScore
4.80
自引率
3.60%
发文量
210
期刊介绍: Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of endocrinology and provides a forum of debate of the highest quality on these issues. Topics of interest include, but are not limited to, diabetes, lipid disorders, metabolic disorders, osteoporosis, interdisciplinary practices in endocrinology, cardiovascular and metabolic risk, aging research, obesity, traditional medicine, pychosomatic research, behavioral medicine, ethics and evidence-based practices.As of Jan 2018 the journal is published by Springer as a hybrid journal with no article processing charges. All articles published before 2018 are available free of charge on springerlink.Unofficial 2017 2-year Impact Factor: 1.816.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信